Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-714-1 | CAS number: 853-23-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity - oral: No reliable, key repeated dose toxicity study is available for T008506. Therefore, reliable data from the supporting substance Dehydroepiandrosterone (DHEA) is used to cover this endpoint. In a one-year, chronic toxicity study in cynomolgus monkey, an NOAEL of 10 mg/kg/d was established. This NOAEL is also considered valid for the target substance T008506. Based on the results and the CLP Regulation, the substance is not to be classified as STOT RE.
Repeated dose toxicty - inhalation: A key study is available for the oral route of exposure. According to the REACH regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the inhalation route of exposure.
Repeated dose toxicty - dermal: A key study is available for the oral route of exposure. According to the REACH regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the dermal route of exposure.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Data from the supporting substance Dehydroepiandrosterone is used to cover this endpoint. The justification for read across is attached in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Assumes that the observed effects on endocrine organ weights are pharmacologic.
- Remarks on result:
- other:
- Remarks:
- This NOAEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Key result
- Critical effects observed:
- no
- Conclusions:
- No reliable repeated dose toxicity study is available for Dehydroepiandrosterone acetate. Therefore, reliable data from the supporting substance Dehydroepiandrosterone (DHEA) is used to cover this endpoint. In a one year monkey oral toxicology study, DHEA produced no adverse effects in male and female monkeys up to 10 mg/kg/day. Changes in endocrine organ weights (ovary, uterus, vagina, pituitary in females and epididymis, testis, spleen and thymus in males) were attributed to estrogenic/androgenic effects that were assumed to be pharmacologic in nature. A NOAEL of 10 mg/kg was identified for male and female monkeys. DHEA is considered to be a worst case read-across substance for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Endpoint:
- chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Data from the supporting substance Dehydroepiandrosterone is used to cover this endpoint. The justification for read across is attached in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- gross pathology
- histopathology: non-neoplastic
- Remarks on result:
- other:
- Remarks:
- This LOAEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- histopathology: non-neoplastic
- Remarks on result:
- other:
- Remarks:
- This NOAEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (nominal)
- System:
- female reproductive system
- Organ:
- ovary
- uterus
- vagina
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 100 mg/kg bw/day (nominal)
- System:
- endocrine system
- Organ:
- adrenal glands
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- No reliable repeated dose toxicity study is available for Dehydroepiandrosterone acetate. Therefore, reliable data from the supporting substance Dehydroepiandrosterone (DHEA) is used to cover this endpoint. In a 6 month rat oral toxicology study of DHEA, estrogen/androgen related effects were observed. In females, this included minimal to slight squamous metaplasia of the glandular epithelium of the uterus at doses of 10 to 100 mg/kg. In males, this included minimal to slight diffuse vacuolation of adrenal cortical cells and reductions in body weight/body weight gain at a dose of 100 mg/kg. A NOAEL was not determined for female rats (LOAEL = 10 mg/kg), while a NOAEL of 10 mg/kg was identified for male rats. DHEA is considered to be a worst case read-across substance for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- Data from the supporting substance Dehydroepiandrosterone is used to cover this endpoint. The justification for read across is attached in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 30 mg/kg bw/day (nominal)
- Based on:
- other: Dehydroepiandrosterone
- Sex:
- female
- Basis for effect level:
- clinical biochemistry
- histopathology: non-neoplastic
- other: Vaginal cytology data indicated reproductive cycle arrest in the estrus stage.
- Remarks on result:
- other:
- Remarks:
- This LOAEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 30 mg/kg bw/day (nominal)
- Based on:
- other:
- Remarks:
- Dehydroepiandrosterone
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- other: All other endocrinologic parameters measured
- Remarks on result:
- other:
- Remarks:
- This NOAEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Dose descriptor:
- LOEL
- Effect level:
- ca. 150 mg/kg bw/day (nominal)
- Based on:
- other:
- Remarks:
- Dehydroepiandrosterone
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- other: Plasma androstenedione level
- Remarks on result:
- other:
- Remarks:
- This LOEL is considered relevant for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Conclusions:
- No reliable repeated dose toxicity study is available for Dehydroepiandrosterone acetate. Therefore, reliable data from the supporting substance Dehydroepiandrosterone (DHEA) is used to cover this endpoint. The endocrinologic effects of this read-across substance was examined in adult male and female Fischer 344 rats following 28 days of daily oral treatment (gavage). Initial doses tested were 30 and 300 mg/kg/day (n=12/sex/group), which is equivalent to 104 and 1,042 µmoles/kg/day DHEA. However, due to weight loss at the high dose, this dose was lowered to 150 mg/kg/day (521 µmoles/ kg/day DHEA). Administration of DHEA resulted in dose-dependent increases in plasma DHEA and DHEA-Sulfate 1 hour after dosing in week 4. DHEA produced an estrogenic effect in female rats expressed as decreased plasma follicle stimulating hormone (FSH) and luteinizing hormone (LH), inhibition of ovulation, prolonged estrus, and increased uterine estrogen receptors. DHEA produced histologic and endocrinologic changes in reproductive tissues in female rats. Decreased corpora lutea in the ovaries was produced by DHEA in a dose-dependent fashion, which indicated that the estrus cycle was arrested in the estrus stage so that ovulation failed to occur. DHEA also increased plasma levels of androstenedione in males and females. Except for increased plasma levels of androstenedione, no other endocrinologic effects were elicited in males by DHEA administration. DHEA is considered to be a worst case read-across substance for Dehydroepiandrosterone acetate. Justification for this read across approach is included in IUCLID section 13.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- The dates of the study were not reported in the publication.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- Study not performed according to GLP, but is sufficient to accept the data and is nevertheless well documented and scientifically acceptable.
- Principles of method if other than guideline:
- Experiment 1 (Tagliaferro, et al., 1986): The purpose of this study was to examine the effects of DHEA acetate on resting metabolism and body composition of males versus females. Five male and 5 female 15-week old Sprague-Dawley outbred rats were administered Dehydroepiandrosterone acetate (DHEA acetate) in a commercial, nonpurifed diet (6 g DHEA acetate/kg diet) for 11 weeks to examine the effects of DHEA acetate on resting metabolism and body composition of male versus female animals. Control animals (5 males and 5 females) were fed nonpurifed diet only. Food intake and body weight were recorded daily. Resting heat production of metabolic rate (RMR) was measured during weeks 0, 6 and 11 of the experiment by indirect respiration calorimetry in an open-loop system. At the end of the 12th week, animals were killed by decapitation. Blood was collected and the caudate lobe of the liver was removed and frozen in liquid nitrogen. The gastrointestinal tract was removed, washed, dried and returned to the body cavity. Blood sera, hepatic tissue and carcasses were frozen at -20 degrees C for future analyses, including body composition (total moisture, fat and nitrogen), hepatic glucose-6-phosphate dehydrogenase activity and serum triglycerides.
Experiment 2 (Tagliaferro, et al., 1986): Six adult (age not specified) male rats (strain not specified) were housed in metabolic cages equipped with feeding tunnels and urine collection trays. To establish baseline, all rats were fed nonpurified, commercial diet for one week; food and water intakes, urine volume and acetoacetate levels in 24-h urine sample were measured daily during the baseline week. For 15 weeks, 3 animals remained on the nonpurified diet, while 3 animals were fed 6 g DHEA acetate/kg diet. During weeks 1-4, the same measurements performed during baseline were made. After 15 weeks, the animals were killed by decapitation. Blood was collected to measure DHEA levels. Adrenal glands, liver, heart, skeletal muscle and interscapular brown adipose tissue were removed, homogenized in a buffered solution and frozen at -20 degrees C for future analyses, including specific activity of citrate synthase as a marker of oxidative metabolism.
Experiment 3 (Leighton, et al., 1987): This study was a follow-up study to Tagliaferro, et al., 1986. Its purpose was to examine the effectes of DHEA acetate on peroxisomal enzymes fatty acyl-CoA and catalase and on mitochondrial citrate synthase. Six male and 6 female 15-week old Wistar rats were administered Dehydroepiandrosterone acetate (DHEA acetate) in a commercial, nonpurifed diet (6 g DHEA acetate/kg diet) for 6 weeks to examine the effects of DHEA acetate on activities of peroxisomal fatty acyl-coenzyme (CoA) oxidase, catalase and mitochondrial citrate synthase. Control animals (6 males and 6 females) were fed nonpurifed diet only. After 6 weeks, the animals were killed by cervical dislocation. Livers were removed as rapidly as possible, weighed, then divided in halves. One half was used for assay of enzyme of activities, while the other half was stored in liquid nitrogen. - GLP compliance:
- no
- Specific details on test material used for the study:
- EXPERIMENTS 1, 2 & 3: Dehydroepiandrosterone acetate
SOURCE OF TEST MATERIAL (Dehydroepiandrosterone acetate; DHEA acetate)
- Source: Sigma Chemical Co., St. Louis, Missouri, USA
- Purity: Not specified
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of the test material: Not specified
- Solubility and stability of the test substance in the solvent/vehicle: Not specified
FORM AS APPLIED IN TEST
- DHEA acetate was mixed with nonpurified diet (6 g DHEA acetate/kg diet) and fed to animals ad libitum - Species:
- rat
- Strain:
- other: Experiment 1: Sprague-Dawley outbred Experiment 2: strain not specified Experiment 3: Wistar
- Details on test animals or test system and environmental conditions:
- EXPERIMENT 1
TEST ANIMALS
- Source: Charles River (Wilmington, Massachusetts, USA)
- Age: 15 weeks
- Weight: 469 +/- 9.9 g (males); 283 +/- 6.1 g (females)
- Housing: Animals were housed individually in stainless steel cages equipped with feeding tunnels.
- Diet: Ad libitum; commercial, nonpurified diet (Ralston-Purina #5001, St. Louis, Missori, USA)
- Water: Ad libitum; tap water
ENVIRONMENTAL CONDITIONS
- Temperature: 26 degrees C
- Humidity (%): not specified
- Photoperiod (hrs dark / hrs light): 12-hr light-dark cycle (0800-2000)
EXPERIMENT 2
TEST ANIMALS
- Source: not specified
- Age: not specified
- Weight: not specified
- Housing: Animals were housed individually in metabolic cages equipped with feeding tunnels and collection trays for urine.
- Diet: Ad libitum; commercial, nonpurified diet (Ralston-Purina #5001, St. Louis, Missori, USA)
- Water: Ad libitum; tap water
ENVIRONMENTAL CONDITIONS
- Temperature: not specified
- Humidity (%): not specified
- Photoperiod (hrs dark / hrs light): not specified
EXPERIMENT 3
TEST ANIMALS
- Source: Batin and Kingman (Hull, United Kingdom)
- Age: 15 weeks
- Weight: 349 +/- 6 g (males); 216 +/- 5 g (females)
- Housing: Animals were housed in pairs in 41 x 56 cm wire-mesh cages.
- Diet: Ad libitum; commercial powdered nonpurified diet (S.D.S. Witham, Essex, United Kingdom)
- Water: Ad libitum; tap water
ENVIRONMENTAL CONDITIONS
- Temperature: 22 degrees C
- Humidity (%): not specified
- Photoperiod (hrs dark / hrs light): Lights on 0600-2000 - Route of administration:
- oral: feed
- Details on route of administration:
- EXPERIMENTS 1, 2 & 3:
- Method: Animals were fed nonpurified diet mixed with DHEA acetate (6 g/kg diet)
- Frequency: Animals were fed ad libitum - Vehicle:
- not specified
- Details on oral exposure:
- EXPERIMENTS 1, 2 & 3:
- Animals were fed nonpurified diet mixed with DHEA acetate (6 g/kg diet) ad libitum - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Experiment 1: 11 weeks
Experiment 2: 6 weeks
Experiment 3: 15 weeks - Frequency of treatment:
- Animals were fed nonpurified diet mixed with DHEA acetate (6 g/kg diet) ad libitum
- Dose / conc.:
- 0 mg/kg diet
- Remarks:
- Control Group
- Dose / conc.:
- 6 000 mg/kg diet
- Remarks:
- Dose Group 1
- No. of animals per sex per dose:
- Experiment 1: 5 males/5 females
Experiment 2: 3 males
Experiment 3: 6 males/6 females - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: No information was provided in the publication on dose selection.
- Rationale for animal assignment: Animals were assigned randomly to either the DHEA-treated or the control group. - Positive control:
- No
- Observations and examinations performed and frequency:
- Experiment 1 (Tagliaferro, et al., 1986):
CAGE SIDE OBSERVATIONS: Not specified.
DETAILED CLINICAL OBSERVATIONS: Not specified.
BODY WEIGHT: Body weight was recorded daily.
FOOD CONSUMPTION: Food intake was recorded daily.
OTHER:
- Resting heat production of metabolic rate (RMR): RMR was measured during weeks 0, 6 and 11 of the experiment by indirect respiration calorimetry in an open-loop system.
- Carcass was evaluated for body composition (total moisture, fat and nitrogen).
- Hepatic tissue was evaluated for hepatic glucose-6-phosphate dehydrogenase activity.
- Blood sera was evaluated for serum triglycerides.
Experiment 2 (Tagliaferro, et al., 1986):
CAGE SIDE OBSERVATIONS: Not specified.
DETAILED CLINICAL OBSERVATIONS: Not specified.
BODY WEIGHT: Not specified.
FOOD CONSUMPTION: Food intake was recorded daily.
WATER CONSUMPTION: Water intake was recorded daily.
OTHER:
- Urine volume: Measured daily (24-h urine sample).
- Acetoacetate levels in 24-h urine sample were measured daily.
- Adrenal glands, liver, heart, skeletal muscle and interscapular brown adipose tissue were removed, homogenized in a buffered solution and frozen at -20 degrees C for future analyses, including specific activity of citrate synthase as a marker of oxidative metabolism.
- DHEA was measured in the blood collected at 15 weeks.
Experiment 3 (Leighton, et al., 1987):
CAGE SIDE OBSERVATIONS: Not specified.
DETAILED CLINICAL OBSERVATIONS: Not specified.
BODY WEIGHT: Body weight measurements were taken, but the schedule was not specified. Initial and final body weights were reported in the publication, but no body weights for other intervals.
FOOD CONSUMPTION: Not specified.
ORGAN WEIGHTS: Livers were weighed after terminal sacrifice.
OTHER:
- Enzyme activities of peroxisomal fatty acyl-coenzyme (CoA) oxidase, catalase and mitochondrial citrate synthase were measured in treated and untreated animal livers. - Sacrifice and pathology:
- Experiment 1 (Tagliaferro, et al., 1986):
SACRIFICE
- Animals were killed by decapitation.
GROSS PATHOLOGY
- Not specified.
CLINICAL BIOCHEMISTRY
- Blood sera was analyzed for serum triglycerides.
ORGAN WEIGHTS
- Hepatic lobe weight (caudate lobe)
HISTOPATHOLOGY
- Not specified.
OTHER
- The gastrointestinal tract was removed, washed, dried and returned to the body cavity.
- Carcasses were frozen at -20 degrees C for future analyses, including body composition (total moisture, fat and nitrogen).
Experiment 2 (Tagliaferro, et al., 1986):
SACRIFICE
- Animals were killed by decapitation.
GROSS PATHOLOGY
- Not specified.
HAEMATOLOGY/CLINICAL BIOCHEMISTRY
- Blood was collected to measure DHEA levels.
ORGAN WEIGHTS
- Not specified.
HISTOPATHOLOGY
- Not specified.
OTHER
- Adrenal glands, liver, heart, skeletal muscle and interscapular brown adipose tissue were removed, homogenized in a buffered solution and frozen at -20 degrees C for future analyses, including specific activity of citrate synthase as a marker of oxidative metabolism.
Experiment 3 (Leighton, et al., 1987):
SACRIFICE
- Animals were killed by cervical dislocation.
OTHER
- Livers were removed as rapidly as possible, weighed, then divided in halves. One half was used for assay of enzyme activities of peroxisomal fatty acyl-coenzyme (CoA) oxidase, catalase and mitochondrial citrate synthase. The other half of the liver was stored in liquid nitrogen. - Clinical signs:
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality was described for any of the three experiments.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Experiment 1: Inhibitory effects of DHEA treatment on weight gain were observed with two weeks following beginning of treatment. DHEA-treated animals weighed significantly less than controls after six weeks and continued to the end of treatment. Paired comparisons between groups indicated that only the difference between male groups was statistically significant.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Experiments 1 and 2: Food intake was found not to change from baseline levels and was not significantly different between treated and control animals.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Experiment 2: Water intake was found not to change from baseline levels and was not significantly different between treated and control animals.
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Experiment 1: Serum triglyceride levels were lower in the DHEA-treated group.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Experiment 2: Urine volume and urinary ketone levels were found not to change from baseline levels and were not significantly different from controls.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Experiment 1: Hepatic caudal lobes of DHEA-treated animals were heavier than controls when expressed on a relative weight basis.
Experiment 3: Mean liver weights (g/kg body weight) of the treated male and female groups were significantly heavier by 20 and 65%, respectively, than those of the control animals. - Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Experiment 1:
- Resting heat production of metabolic rate (RMR): At the end of weeks 6 and 11, the RMR of both treated males and females was higher than the controls (ANOVA, p < 0.01).
- Body composition (total moisture, fat and nitrogen): No statistically significant differences in body water content was observed between DHEA-treated and control animals within sex groups. DHEA decreased both total and relative body fat in males and females, but the finding was statistically significant only in females. Relative content of body protein was increased in both treated males and females, but significantly more so for females than males. Relative ash content was increased in both treated males and females, but this finding was statistically significant only in the treated females. DHEA decreased total carcass energy in both sexes, but the finding was statistically significant only in females.
- Hepatic glucose-6-phosphate dehydrogenase activity: Specific activity of G6PDH was suppressed in animals.
Experiment 2:
- Citrate synthase activity (marker of oxidative metabolism) in adrenal glands, liver, heart, skeletal muscle and interscapular brown adipose tissue: The specific activity of citrate synthase was not affected significantly by DHEA treatment.
Experiment 3:
- Enzyme activities of peroxisomal fatty acyl-coenzyme (CoA) oxidase, catalase and mitochondrial citrate synthase: Specific activity of peroxisomal enzymes fatty acyl-CoA oxidase and catalase was significantly higher in the liver tissue of DHEA-treated groups than in control groups. There were no differences in citrate synthase activity. Catalase activity on only treated females was significantly higher (30%) than controls. - Dose descriptor:
- LOEL
- Effect level:
- 6 000 mg/kg diet
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- organ weights and organ / body weight ratios
- other: Increased resting heat production, lower hepatic glucose-6-phosphate dehydrogenase activity, lower body fat, increased body water, increased protein and ash, increased peroxisomal fatty acyl-CoA oxidase and catalase activities
- Conclusions:
- In the three experiments undertaken for this study, DHEA acetate treatment resulted in increased resting heat production, reduced body weights (statistically significant only in males) without an effect on food intake, reduced serum triglycerides, increased liver weights (significant in males and females), lower body fat (significant only in females), higher body protein and ash (significant in females only), and significantly higher specific activity of the peroxisomal enzymes fatty acyl-CoA oxidase and catalase in the liver tissue of DHEA-treated animals. The study authors conclude that DHEA acetate treatment affects body weight, body composition and utilization of dietary energy by impairing fat synthesis and promoting fat-free tissue deposition and resting heat production. The results also support the hypothesis that the inhibitory effect of DHEA on energy storage as fat is mediated in part by increased beta-oxidation of fatty acids in peroxisomes.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 10 mg/kg bw/day
- Study duration:
- chronic
- Species:
- monkey
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: oral
Four publications of repeated dose toxicity studies are considered: 1 study with the target substance T008506 and 3 with the supporting substance DHEA.
6, 11 or 15 weeks dosing of T008506 in rat (Tagliaferro et al., 1986; Leighton et al., 1987)
DHEA acetate (or T008506) was dosed to rats at 6000mg/kg/day via diet for 6, 11 or 15 weeks. The study concluded that DHEA acetate treatment affects body weight, body composition and utilization of dietary energy by impairing fat synthesis and promoting fat-free tissue deposition and resting heat production. These results also support the hypothesis that the inhibitory effects of DHEA on energy storage as fat is mediated in part by increased beta-oxidation of fatty acids in peroxisomes. An LOEL of 6000 mg/kg/d was established.
28-day repeated dose toxicity study in rat (Brown et al., 2003) with DHEA
The endocrinologic effects of DHEA were examined in adult male and female Fischer 344 rats following 28 days of daily oral treatment (gavage) with 30 or 300 mg/kg/day. DHEA produced an estrogenic effect in female rats expressed as decreased plasma FSH and LH, inhibition of ovulation, prolonged estrus and increased uterine estrogen receptors. DHEA produced histologic and endocrinologic changes in reproductive tissues in female rats. Decreased corpora lutea in the ovaries were observed in a dose-dependent fashion, which indicated that the estrus cycle was arrested in the estrus stage so that ovulation failed to occur.
6-month repeated dose toxicity in rat with DHEA
Male and female rats were dosed with 10 or 100 mg/kg/d DHEA via oral gavage during 6 months. Estrogen/androgen related effects were observed. In females, this included minimal to slight squamous metaplasia of the glandular epithelium of the uterus at doses of 10 to 100 mg/kg/day. In males, this included minimal to slight diffuse vacuolation of adrenal cortical cells and reductions in body weight/body weight gain at a dose of 100 mg/kg/d. An NOAEL was not determined for female rats (LOAEL = 10 mg/kg), while an NOAEL of 10 mg/kg was identified for male rats.
1-year chronic toxicity study in rat with DHEA
Male and female cynomolgus monkey were dosed daily with 2 or 10 mg/kg/d during 1 year via oral gavage. DHEA produced no adverse effects in male and female monkeys up to 10 mg/kg/d. Changes in endocrine organ weights (ovary, uterus, vagina, pituitary in females and epididymides, testis, spleen, and thymus in males) were attributed to estrogenic/androgenic effects that were assumed to be pharmacologic in nature. A NOAEL of 10 mg/kg/d was identified for male and female monkeys.
In conclusion, DHEA is considered to be a worst-case read-across substance for T008506. Based on the results described above, the chronic toxicity study in cynomolgus monkey with NOAEL = 10 mg/kg/day is considered the key study and key value.
Repeated dose toxicity: inhalation
A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the inhalation route of exposure.
Repeated dose toxicity: dermal
A key study is available for the oral route of exposure. According to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (column 2, annex VIII, section 8.6.1). Therefore, it is not necessary to perform a repeated dose toxicity study via the dermal route of exposure.
Justification for classification or non-classification
Based on the results of the repeated dose toxicity via the oral route and the criteria of the CLP Regulation, T008506 should not be classified as STOT repeated exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.